Patents by Inventor Ricardo Cibotti

Ricardo Cibotti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20250101116
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: February 27, 2023
    Publication date: March 27, 2025
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20200172625
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 4, 2020
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20200055944
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 20, 2020
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 10301390
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20180244791
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: May 4, 2018
    Publication date: August 30, 2018
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 9988459
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: June 5, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20180118839
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: September 21, 2017
    Publication date: May 3, 2018
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
    Publication number: 20170121771
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 11, 2016
    Publication date: May 4, 2017
    Applicant: MEDIMMUNE, LLC
    Inventors: YIHONG YAO, BAHIJA JALLAL, RICARDO CIBOTTI, ANTHONY COYLE, PETER KIENER
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
    Publication number: 20150147336
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: Yihong YAO, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
    Publication number: 20150044222
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 12, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Yihong YAO, Bahija JALLAL, Ricardo CIBOTTI, Anthony COYLE, Peter KIENER
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    Publication number: 20110287022
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognoses to patients having IFN?-induced disorders.
    Type: Application
    Filed: June 19, 2009
    Publication date: November 24, 2011
    Applicant: Medlmmune, LLC
    Inventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener, Barbara White
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20110059078
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: February 6, 2009
    Publication date: March 10, 2011
    Applicant: Medimmune, LLC
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    Publication number: 20100261172
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: May 5, 2008
    Publication date: October 14, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    Publication number: 20100143372
    Abstract: The present invention encompasses type-1 IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 10, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
  • COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
    Publication number: 20100093611
    Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.
    Type: Application
    Filed: May 16, 2008
    Publication date: April 15, 2010
    Inventors: Stephen K. Horrigan, Qin Zong, Daniel Soppet, Juana Castaneda, Bo Chen, Ricardo Cibotti, Laurent P. Audoly, Anthony Coyle, Peter Kiener